| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:7 | Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female | Reproductive system disease; Endocrine system disease; Reproductive system disease | Under Review | Rat, Mouse, Human | 0.2 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
| AOP:8 | Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Nervous system disease | Under Development | Rat | 0.22 | KE:757 | Hippocampal anatomy, Altered |
| KE:295 | Induction, Upregulation of glucuronyltransferase activity | ||||||
| AOP:15 | Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations | Genetic disease | WPHA/WNT Endorsed | Mus musculus, Drosophila melanogaster, Oryzias latipes, Syrian golden hamster | 0.25 | KE:155 | Inadequate DNA repair |
| AOP:23 | Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish) | Unclassified | WPHA/WNT Endorsed | Pimephales promelas | 0.1 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
| AOP:25 | Aromatase inhibition leading to reproductive dysfunction | Unclassified | WPHA/WNT Endorsed | Fathead minnow, Medaka, Zebrafish | 0.12 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
| AOP:28 | Cyclooxygenase inhibition leading reproductive failure | Reproductive system disease | - | 0.17 | KE:49 | Reduction, Ca and HCO3 transport to shell gland | |
| AOP:37 | PPARα activation leading to hepatocellular adenomas and carcinomas in rodents | Cancer; Gastrointestinal system disease | Under Development | Mouse, Rat | 0.2 | KE:716 | Increase, cell proliferation (hepatocytes) |
| AOP:38 | Protein Alkylation leading to Liver Fibrosis | Gastrointestinal system disease | WPHA/WNT Endorsed | Human, Rat | 0.43 | KE:1493 | Increased Pro-inflammatory mediators |
| KE:68 | Accumulation, Collagen | ||||||
| KE:55 | Increase, Cell injury/death | ||||||
| AOP:39 | Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response | Respiratory system disease | Under Development | Human, Mouse | 0.2 | KE:272 | Activation/Proliferation, T-cells |
| AOP:40 | Covalent Protein binding leading to Skin Sensitisation | Integumentary system disease | WPHA/WNT Endorsed | Mouse, Human | 0.2 | KE:272 | Activation/Proliferation, T-cells |
| AOP:43 | Disruption of VEGFR Signaling Leading to Developmental Defects | Unclassified | WPHA/WNT Endorsed | Mouse, Zebrafish, Rats, Human | 0.2 | KE:28 | Reduction, Angiogenesis |
| AOP:58 | NR1I3 (CAR) suppression leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | Human, Mouse, Rat | 0.06 | KE:454 | Increased, Triglyceride formation |
| AOP:60 | NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.08 | KE:454 | Increased, Triglyceride formation | |
| AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive system disease | - | Rattus norvegicus | 0.14 | KE:496 | Increased apoptosis, decreased fetal/adult Leydig Cells |
| AOP:73 | Xenobiotic Inhibition of Dopamine-beta-Hydroxylase and subsequent reduced fecundity | Unclassified | - | 0.15 | KE:10059 | Decreased LH surge for 24 hours | |
| KE:531 | Decreased, LH Surge | ||||||
| AOP:77 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1 | Unclassified | - | Honey bee | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:78 | Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1 | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:80 | Nicotinic acetylcholine receptor activation contributes to accumulation of damaged mitochondrial DNA and leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:664 | Overwhelmed, Mitochondrial DNA repair mechanisms |
| AOP:87 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:88 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste | Unclassified | - | Honey bee | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:89 | Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:90 | Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:99 | Histamine (H2) receptor antagonism leading to reduced survival | Unclassified | - | Zebrafish | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:105 | Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary system disease | - | Rattus norvegicus | 0.17 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
| AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal system disease | Under Review | Rattus norvegicus, Mus musculus | 0.2 | KE:716 | Increase, cell proliferation (hepatocytes) |
| AOP:108 | Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | - | Mus musculus, Rattus norvegicus | 0.17 | KE:768 | Increase, Cytotoxicity |
| AOP:109 | Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse) | Cancer; Respiratory system disease | - | Mus musculus | 0.2 | KE:734 | Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) |
| AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.29 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | ||||||
| AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive system disease; Cancer | - | Rattus norvegicus | 0.17 | KE:111 | Agonism, Estrogen receptor |
| AOP:113 | Glutamate-gated chloride channel activation leading to acute mortality | Unclassified | - | Bombus impatiens, Chaetanaphothrips orchidii, Radopholus similis, Daphnia magna, Orius insidiosus, Hymenoptera, Helicoverpa zea, Lepidoptera, Liriomyza trifolii, Orius isidiosus, Acyrthosiphon kondoi | 0.17 | KE:761 | Increased, Chloride conductance |
| AOP:114 | HPPD inhibition leading to corneal papillomas and carcinomas (in rat) | Cancer | - | Rattus norvegicus | 0.33 | KE:778 | Increase, Regenerative cell proliferation (corneal cells) |
| KE:777 | Increase, Inflammation (corneal cells) | ||||||
| AOP:115 | Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat) | Cancer | - | Mus musculus, Rattus norvegicus | 0.4 | KE:149 | Increase, Inflammation |
| KE:781 | Increase, Regenerative cell proliferation (forestomach epithelial cells) | ||||||
| AOP:116 | Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary system disease | - | Rattus norvegicus | 0.25 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
| AOP:117 | Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | Under Development | Mus musculus, Rattus norvegicus | 0.25 | KE:716 | Increase, cell proliferation (hepatocytes) |
| AOP:118 | Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | - | Mus musculus, Rattus norvegicus | 0.25 | KE:787 | Increase, Regenerative cell proliferation (hepatocytes) |
| AOP:122 | Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation | Unclassified | - | Pimephales promelas | 0.1 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
| AOP:123 | Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription | Unclassified | - | Pimephales promelas | 0.09 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
| AOP:124 | HMG-CoA reductase inhibition leading to decreased fertility | Reproductive system disease | - | Rattus rattus | 0.17 | KE:807 | Decreased, cholesterol |
| AOP:126 | Alpha-noradrenergic antagonism leads to reduced fecundity via delayed ovulation | Unclassified | - | 0.15 | KE:10059 | Decreased LH surge for 24 hours | |
| KE:531 | Decreased, LH Surge | ||||||
| AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign neoplasm; Respiratory system disease | Under Review | 0.43 | KE:868 | Increase, Tissue Degeneration, Necrosis & Atrophy | |
| KE:768 | Increase, Cytotoxicity | ||||||
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:144 | Endocytic lysosomal uptake leading to liver fibrosis | Gastrointestinal system disease | Under Review | Human, Mouse, Rat | 0.33 | KE:1493 | Increased Pro-inflammatory mediators |
| KE:68 | Accumulation, Collagen | ||||||
| KE:55 | Increase, Cell injury/death | ||||||
| AOP:149 | Peptide Oxidation Leading to Hypertension | Cardiovascular system disease | Under Development | Human, Mouse, Rat, Cow | 0.2 | KE:933 | KE6 : Depletion, Nitric Oxide |
| KE:937 | KE7 : Impaired, Vasodilation | ||||||
| AOP:160 | Ionotropic gamma-aminobutyric acid receptor activation mediated neurotransmission inhibition leading to mortality | Unclassified | - | Daphnia magna | 0.14 | KE:761 | Increased, Chloride conductance |
| AOP:161 | Glutamate-gated chloride channel activation leading to neurotransmission inhibition associated mortality | Unclassified | - | Nematode, Daphnia magna | 0.14 | KE:761 | Increased, Chloride conductance |
| AOP:164 | Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse | Cancer; Reproductive system disease | - | CD-1 mouse, SD rat | 0.17 | KE:1042 | Proliferation/Clonal Expansion, smooth muscle |
| AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive system disease; Cancer | - | Mouse, Homo sapiens | 0.29 | KE:1067 | Proliferation/Clonal Expansion, aberrant basal cells |
| KE:1065 | Activation, estrogen receptor alpha | ||||||
| AOP:173 | Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis | Musculoskeletal system disease; Respiratory system disease | WPHA/WNT Endorsed | Human, Mouse, Rat | 0.25 | KE:68 | Accumulation, Collagen |
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| AOP:176 | Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
| AOP:188 | Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
| AOP:190 | Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.17 | KE:1829 | Altered, Thyroid hormone-dependent gene expression |
| AOP:191 | Type III iodotyrosine deiodinase (DIO3) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:1829 | Altered, Thyroid hormone-dependent gene expression |
| AOP:192 | Pendrin inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
| AOP:193 | Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
| AOP:194 | Hepatic nuclear receptor activation leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.17 | KE:295 | Induction, Upregulation of glucuronyltransferase activity |
| AOP:195 | 5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase | Unclassified | - | Argopecten irradians, Mercenaria mercenaria, Arctica islandica, Spisula solidissima, Anodonta cygnea, Dreissena polymorpha | 0.12 | KE:1163 | Increased, Reproductive Success |
| AOP:206 | Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis | Musculoskeletal system disease; Respiratory system disease | Under Development | Homo sapiens | 0.17 | KE:149 | Increase, Inflammation |
| AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive system disease | - | Caenorhabditis elegans | 0.38 | KE:1115 | Increase, Reactive oxygen species |
| KE:1281 | Increased, DNA Damage-Repair | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive system disease | WPHA/WNT Endorsed | Rat, Human, Mouse | 0.33 | KE:1505 | Cell cycle, disrupted |
| KE:1262 | Apoptosis | ||||||
| AOP:213 | Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) | Gastrointestinal system disease; Inherited metabolic disorder | - | Vertebrates | 0.17 | KE:1115 | Increase, Reactive oxygen species |
| AOP:219 | Inhibition of CYP7B activity leads to decreased reproductive success via decreased sexual behavior | Unclassified | - | Japanese quail, Cynops pyrrhogaster | 0.17 | KE:1390 | Sexual behavior, decreased |
| AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal system disease | WPHA/WNT Endorsed | Rodents, Homo sapiens | 0.2 | KE:1394 | Induction, persistent proliferation/sustained proliferation |
| AOP:241 | Latent Transforming Growth Factor beta1 activation leads to pulmonary fibrosis | Musculoskeletal system disease; Respiratory system disease | - | 0.17 | KE:68 | Accumulation, Collagen | |
| AOP:245 | Reduction in photophosphorylation leading to growth inhibition in aquatic plants | Unclassified | - | Lemna minor, Lemna gibba | 0.09 | KE:40 | Decrease, Mitochondrial ATP production |
| AOP:258 | Renal protein alkylation leading to kidney toxicity | Urinary system disease | Under Development | Human, Rat, Mouse | 0.2 | KE:40 | Decrease, Mitochondrial ATP production |
| AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.43 | KE:155 | Inadequate DNA repair |
| KE:870 | Increase, Cell Proliferation | ||||||
| KE:1636 | Increase, Chromosomal aberrations | ||||||
| AOP:277 | Impaired IL-1R1 signaling leading to Impaired T-Cell Dependent Antibody Response | Immune system disease | WPHA/WNT Endorsed | Homo sapiens, Mus musculus, Rattus norvegicus | 0.25 | KE:202 | Inhibition, Nuclear factor kappa B (NF-kB) |
| AOP:278 | IKK complex inhibition leading to liver injury | Unclassified | - | 0.25 | KE:55 | Increase, Cell injury/death | |
| KE:202 | Inhibition, Nuclear factor kappa B (NF-kB) | ||||||
| AOP:280 | α-diketone-induced bronchiolitis obliterans | Musculoskeletal system disease; Respiratory system disease | - | 0.14 | KE:149 | Increase, Inflammation | |
| AOP:286 | Mitochondrial complex III antagonism leading to growth inhibition (1) | Unclassified | - | Lemna minor, Daphnia magna, Danio rerio | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:1771 | Decrease, Adenosine triphosphate pool | ||||||
| AOP:287 | Mitochondrial complex III antagonism leading to growth inhibition (2) | Unclassified | - | Lemna minor, Daphnia magna, Danio rerio | 0.5 | KE:1771 | Decrease, Adenosine triphosphate pool |
| KE:1825 | Increase, Cell death | ||||||
| AOP:290 | Mitochondrial ATP synthase antagonism leading to growth inhibition (1) | Unclassified | - | Daphnia magna | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:1771 | Decrease, Adenosine triphosphate pool | ||||||
| AOP:291 | Mitochondrial ATP synthase antagonism leading to growth inhibition (2) | Unclassified | - | Daphnia magna | 0.5 | KE:1771 | Decrease, Adenosine triphosphate pool |
| KE:1825 | Increase, Cell death | ||||||
| AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | Rattus rattus, Mus musculus | 0.22 | KE:1493 | Increased Pro-inflammatory mediators |
| KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | ||||||
| AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | 0.22 | KE:1493 | Increased Pro-inflammatory mediators | |
| KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | ||||||
| AOP:299 | Deposition of energy leading to population decline via DNA oxidation and follicular atresia | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | Mammals | 0.57 | KE:1497 | Increased, recruitment of inflammatory cells |
| KE:870 | Increase, Cell Proliferation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1669 | Increased, DNA damage and mutation | ||||||
| AOP:311 | Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis | Unclassified | - | Daphnia magna, Fish | 0.14 | KE:1115 | Increase, Reactive oxygen species |
| AOP:322 | Alkylation of DNA leading to reduced sperm count | Reproductive system disease | - | 0.2 | KE:155 | Inadequate DNA repair | |
| AOP:323 | PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone | Unclassified | - | Teleost fish | 0.17 | KE:807 | Decreased, cholesterol |
| AOP:334 | Glucocorticoid Receptor Agonism Leading to Impaired Fin Regeneration | Unclassified | - | Teleost fish | 0.17 | KE:2245 | Altered Cell Differentiation Signaling |
| AOP:335 | AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment | Cancer; Urinary system disease | - | Rat | 0.2 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
| AOP:346 | Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Oreochromis niloticus, Chinook salmon, Fathead minnow, European sea bass | 0.2 | KE:1789 | Reduction, 17beta-estradiol synthesis by the undifferentiated gonad |
| AOP:368 | Cytochrome oxidase inhibition leading to increased nasal lesions | Unclassified | - | Rodents, Human | 0.33 | KE:1825 | Increase, Cell death |
| AOP:379 | Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation | Cardiovascular system disease | Under Development | Homo sapiens | 0.14 | KE:1869 | Diminished protective oxidative stress response |
| AOP:382 | Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis | Musculoskeletal system disease; Respiratory system disease | Under Development | 0.5 | KE:68 | Accumulation, Collagen | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1172 | Increased activation, Nuclear factor kappa B (NF-kB) | ||||||
| AOP:383 | Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis | Gastrointestinal system disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:384 | Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease | Urinary system disease | - | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:386 | Deposition of ionizing energy leading to population decline via inhibition of photosynthesis | Reproductive system disease | - | Lemna minor, Chlamydomonas reinhardtii | 0.12 | KE:1115 | Increase, Reactive oxygen species |
| AOP:387 | Deposition of ionising energy leading to population decline via mitochondrial dysfunction | Reproductive system disease | - | Lemna minor | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| KE:40 | Decrease, Mitochondrial ATP production | ||||||
| AOP:397 | Bulky DNA adducts leading to mutations | Genetic disease | Under Development | 0.33 | KE:155 | Inadequate DNA repair | |
| AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.5 | KE:1497 | Increased, recruitment of inflammatory cells | |
| KE:870 | Increase, Cell Proliferation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1669 | Increased, DNA damage and mutation | ||||||
| AOP:410 | GSK3beta inactivation leading to increased mortality via defects in developing inner ear | Unclassified | - | Zebrafish | 0.2 | KE:1825 | Increase, Cell death |
| KE:1008 | Reduced, Hearing | ||||||
| AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital nervous system abnormality; Nervous system disease | - | Homo sapiens, Mus musculus musculus, Rattus norvegicus | 0.14 | KE:1262 | Apoptosis |
| AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | Human | 0.44 | KE:1497 | Increased, recruitment of inflammatory cells |
| KE:870 | Increase, Cell Proliferation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1669 | Increased, DNA damage and mutation | ||||||
| AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory system disease | - | 0.09 | KE:1262 | Apoptosis | |
| AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | Mouse | 0.22 | KE:1821 | Decrease, Cell proliferation |
| KE:1262 | Apoptosis | ||||||
| AOP:464 | Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits | Nervous system disease | - | 0.11 | KE:1825 | Increase, Cell death | |
| KE:389 | Increased, Intracellular Calcium overload | ||||||
| AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.25 | KE:748 | Increased, Estrogen receptor (ER) activity | |
| KE:2050 | Increase, developmental abnormalities | ||||||
| AOP:467 | Knickkopf leading to mortality | Unclassified | - | 0.11 | KE:2050 | Increase, developmental abnormalities | |
| AOP:470 | Deposition of energy leads to abnormal vascular remodeling | Cardiovascular system disease | Under Review | Human, Rat, Mouse, Rabbit | 0.12 | KE:1493 | Increased Pro-inflammatory mediators |
| AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous system disease; Monogenic disease | Under Review | Human, Mouse, Rat, Rhesus monkeys, Rabbit, Guinea pig | 0.3 | KE:155 | Inadequate DNA repair |
| KE:870 | Increase, Cell Proliferation | ||||||
| KE:1636 | Increase, Chromosomal aberrations | ||||||
| AOP:479 | Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress | Cardiovascular system disease; Thoracic disease | Under Development | 0.14 | KE:55 | Increase, Cell injury/death | |
| AOP:480 | Mitochondrial complexes inhibition leading to heart failure via decreased ATP production | Cardiovascular system disease; Thoracic disease | Under Development | 0.2 | KE:40 | Decrease, Mitochondrial ATP production | |
| AOP:482 | Deposition of energy leading to occurrence of bone loss | Musculoskeletal system disease | Under Review | Human, Mouse, Rat, Rhesus monkeys | 0.29 | KE:1825 | Increase, Cell death |
| KE:2245 | Altered Cell Differentiation Signaling | ||||||
| AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | Mouse | 0.33 | KE:1821 | Decrease, Cell proliferation |
| KE:1262 | Apoptosis | ||||||
| AOP:492 | Glutathione conjugation leading to reproductive dysfunction via oxidative stress | Reproductive system disease | - | Mammals, Fish | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired metabolic disease | - | Mus musculus, Homo sapiens | 0.2 | KE:2119 | Insulin resistance, increased |
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive system disease; Cancer | - | 0.22 | KE:854 | Alterations, Cellular proliferation / hyperplasia | |
| KE:1183 | Decreased, Apoptosis (Epithelial Cells) | ||||||
| AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | Murinae gen. sp. | 0.14 | KE:1115 | Increase, Reactive oxygen species |
| AOP:530 | Endocytotic lysosomal uptake leads to intestinal barrier disruption | Gastrointestinal system disease | - | 0.2 | KE:55 | Increase, Cell injury/death | |
| AOP:539 | Decreased Sodium/Potassium ATPase activity leads to Heart failure | Cardiovascular system disease | - | Fish | 0.14 | KE:2261 | Decreased, blood plasma volume |
| AOP:544 | Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation | Nervous system disease | - | Homo sapiens, Mus musculus | 0.17 | KE:149 | Increase, Inflammation |
| AOP:556 | Decreased Na/K ATPase activity leading to heart failure | Cardiovascular system disease | - | 0.17 | KE:389 | Increased, Intracellular Calcium overload | |
| AOP:558 | Phosphodiesterase inhibition leading to heart failure | Cardiovascular system disease | - | Human and other cells in culture, Rodents, Dog, Pig, Zebrafish | 0.17 | KE:389 | Increased, Intracellular Calcium overload |
| AOP:564 | DBDPE-induced inhibition of mitochondrial complex Ⅰ leading to population decline via neurotoxicity and metabotoxicity. | Unclassified | - | Zebrafish | 0.09 | KE:40 | Decrease, Mitochondrial ATP production |
| AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental disorder of mental health | - | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:573 | Inhibition, cytochrome oxidase leads to Increased, pulmonary edema | Respiratory system disease | - | Rodents, Humans | 0.33 | KE:1825 | Increase, Cell death |
| AOP:574 | Inhibition, cytochrome oxidase leads to Loss of olfactory function | Unclassified | - | Rodents, Humans | 0.33 | KE:1825 | Increase, Cell death |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:12 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | Nervous system disease; Developmental disorder of mental health | WPHA/WNT Endorsed | Monkey, Rat, Human, Mouse, Zebrafish | 0.38 | KE:55 | Increase, Cell injury/death |
| KE:52 | Decreased, Calcium influx | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:13 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Monkey sp., Rat | 0.3 | KE:55 | Increase, Cell injury/death |
| KE:52 | Decreased, Calcium influx | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental disorder of mental health | WPHA/WNT Endorsed | Rat, Mouse, Human | 0.3 | KE:1493 | Increased Pro-inflammatory mediators |
| KE:55 | Increase, Cell injury/death | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Rat | 0.33 | KE:55 | Increase, Cell injury/death |
| KE:389 | Increased, Intracellular Calcium overload | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental disorder of mental health | WPHA/WNT Endorsed | Homo sapiens, Rattus sp. | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:63 | Cyclooxygenase inhibition leading to reproductive dysfunction | Reproductive system disease | - | Goldfish, Human, Mouse, Rat | 0.2 | KE:675 | Reduced, Reproductive Success |
| AOP:100 | Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of female spawning behavior | Reproductive system disease | - | Goldfish | 0.29 | KE:675 | Reduced, Reproductive Success |
| KE:672 | Reduced, Prostaglandin F2alpha synthesis, ovary | ||||||
| AOP:101 | Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of pheromone release | Reproductive system disease | - | Goldfish | 0.29 | KE:675 | Reduced, Reproductive Success |
| KE:681 | Decreased, Prostaglandin F2alpha synthesis, ovary | ||||||
| AOP:102 | Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition | Reproductive system disease | - | Goldfish, Human, Rat, Mouse | 0.2 | KE:690 | Reduced, Luteinizing hormone (LH), plasma |
| KE:675 | Reduced, Reproductive Success | ||||||
| AOP:103 | Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint | Reproductive system disease | - | Goldfish, Human, Rat, Mouse | 0.2 | KE:690 | Reduced, Luteinizing hormone (LH), plasma |
| KE:675 | Reduced, Reproductive Success | ||||||
| AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Homo sapiens | 0.33 | KE:757 | Hippocampal anatomy, Altered |
| KE:402 | Cognitive function, decreased | ||||||
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | Homo sapiens, Mus musculus | 0.5 | KE:885 | Increase, Cancer |
| KE:155 | Inadequate DNA repair | ||||||
| AOP:196 | Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation | Respiratory system disease | - | 0.22 | KE:1218 | Opening of calcium channel, Calcium influx | |
| KE:1226 | Increased Respiratory irritability and Chronic Cough, | ||||||
| AOP:204 | 5-hydroxytryptamine transporter inhibition leading to increased reproductive success and population increase | Unclassified | - | 0.12 | KE:1163 | Increased, Reproductive Success | |
| AOP:205 | AOP from chemical insult to cell death | Unclassified | - | Vertebrates | 0.33 | KE:1263 | Necrosis |
| KE:1262 | Apoptosis | ||||||
| AOP:296 | Oxidative DNA damage leading to chromosomal aberrations and mutations | Genetic disease; Chromosomal disease | WPHA/WNT Endorsed | Human, Mice, Rat, Fish | 0.4 | KE:155 | Inadequate DNA repair |
| KE:1636 | Increase, Chromosomal aberrations | ||||||
| AOP:300 | Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | Under Development | Human, Mouse | 0.4 | KE:757 | Hippocampal anatomy, Altered |
| KE:402 | Cognitive function, decreased | ||||||
| AOP:406 | SARS-CoV-2 infection leading to hyperinflammation | Unclassified | - | 0.33 | KE:1869 | Diminished protective oxidative stress response | |
| KE:1868 | Hyperinflammation | ||||||
| AOP:431 | Increased tumor necrosis factor (TNF) leading to increased risk of gestational diabetes mellitus (GDM) | Inherited metabolic disorder | - | Human | 0.2 | KE:1953 | Gestational diabetes mellitus |
| AOP:432 | Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia | Hematopoietic system disease; Cancer | - | Homo sapiens, Mus musculus | 0.36 | KE:1493 | Increased Pro-inflammatory mediators |
| KE:1955 | Acute Myeloid Leukemia | ||||||
| KE:155 | Inadequate DNA repair | ||||||
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:442 | Binding to voltage gate sodium channels during development leads to cognitive impairment | Cognitive disorder | Under Review | Rattus norvegicus, Mouse, Humans | 0.29 | KE:757 | Hippocampal anatomy, Altered |
| KE:402 | Cognitive function, decreased | ||||||
| AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited metabolic disorder | - | Human | 0.33 | KE:2119 | Insulin resistance, increased |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| AOP:468 | Binding of SARS-CoV-2 to ACE2 leads to hyperinflammation (via cell death) | Unclassified | - | 0.38 | KE:1868 | Hyperinflammation | |
| KE:1825 | Increase, Cell death | ||||||
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:475 | Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons | Developmental disorder of mental health | Under Development | Mouse, Rat, Human, Caenorhabditis elegans | 0.25 | KE:389 | Increased, Intracellular Calcium overload |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental disorder of mental health | Under Review | Mouse, Rat, Rabbit, Dog, Pigs, Cow, Human | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:485 | Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:486 | Binding to the extracellular protein laminin leading to decreased cognitive function | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:490 | Co-activation of IP3R and RyR leads to reduced IQ through non-cholinergic mechanisms | Developmental disorder of mental health | - | 0.18 | KE:55 | Increase, Cell injury/death | |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited metabolic disorder; Disease of metabolism | - | 0.25 | KE:2119 | Insulin resistance, increased | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:498 | Increased LCN2/iron complex leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.25 | KE:2150 | Neurological disorder |
| AOP:499 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.25 | KE:341 | Impairment, Learning and memory |
| AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.43 | KE:1115 | Increase, Reactive oxygen species |
| KE:1262 | Apoptosis | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.25 | KE:2150 | Neurological disorder |
| AOP:504 | SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level | Unclassified | - | Mammals | 0.33 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | Mouse, Rat, Human | 0.2 | KE:341 | Impairment, Learning and memory |
| AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.08 | KE:341 | Impairment, Learning and memory | |
| AOP:533 | Retinoic acid receptor antagonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.17 | KE:341 | Impairment, Learning and memory | |
| AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | Vertebrates | 0.5 | KE:885 | Increase, Cancer |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental disorder of mental health | - | Mouse, Human | 0.33 | KE:389 | Increased, Intracellular Calcium overload |
| KE:1262 | Apoptosis | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:561 | Aromatase induction leading to estrogen receptor alpha activation via increased estradiol | Unclassified | - | Vertebrates | 0.2 | KE:1065 | Activation, estrogen receptor alpha |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:16 | Acetylcholinesterase inhibition leading to acute mortality | Unclassified | Under Development | 0.14 | KE:12 | Acetylcholinesterase (AchE) Inhibition | |
| AOP:21 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 | Unclassified | WPHA/WNT Endorsed | Zebrafish, Medaka, Gallus gallus | 0.2 | KE:18 | Activation, AhR |
| AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal system disease | Under Development | Humans | 0.38 | KE:41 | Inhibition, Bile Salt Export Pump (ABCB11) |
| KE:149 | Increase, Inflammation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal system disease | Under Review | Rattus sp. ABTC 42503, Mus sp. 2000082 | 0.6 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
| KE:165 | Activation, Long term AHR receptor driven direct and indirect gene expression changes | ||||||
| KE:853 | Changes/Inhibition, Cellular Homeostasis and Apoptosis | ||||||
| AOP:62 | AKT2 activation leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.25 | KE:486 | systemic inflammation leading to hepatic steatosis | |
| AOP:69 | Modulation of Adult Leydig Cell Function Subsequent to Decreased Cholesterol Synthesis or Transport in the Adult Leydig Cell | Reproductive system disease | - | Rattus norvegicus, Homo sapiens | 0.2 | KE:642 | Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol |
| AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.43 | KE:279 | Thyroperoxidase, Inhibition |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | ||||||
| AOP:121 | Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat) | Cancer; Urinary system disease | - | Mus musculus, Rattus norvegicus | 0.4 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
| KE:793 | Increase, Urinary bladder calculi | ||||||
| AOP:128 | Kidney dysfunction by decreased thyroid hormone | Urinary system disease | Under Development | Sprague-Dawley, Homo sapiens | 0.09 | KE:277 | Thyroid hormone synthesis, Decreased |
| AOP:131 | Aryl hydrocarbon receptor activation leading to uroporphyria | Inherited metabolic disorder | WPHA/WNT Endorsed | Mouse, Rat, Human, Japanese quail, Chicken, Herring gull, Common Starling | 0.33 | KE:18 | Activation, AhR |
| KE:850 | Induction, CYP1A2/CYP1A5 | ||||||
| AOP:148 | EGFR Activation Leading to Decreased Lung Function | Respiratory system disease | Under Development | Human, Mouse, Rat | 0.25 | KE:941 | Activation, EGFR |
| AOP:150 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF | Unclassified | WPHA/WNT Endorsed | Chicken, Zebrafish, Mouse, Rattus norvegicus | 0.14 | KE:18 | Activation, AhR |
| AOP:151 | AhR activation leading to preeclampsia | Cardiovascular system disease | Under Development | Homo sapiens, Mus musculus | 0.14 | KE:18 | Activation, AhR |
| AOP:159 | Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.25 | KE:279 | Thyroperoxidase, Inhibition |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| AOP:175 | Thyroperoxidase inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.5 | KE:279 | Thyroperoxidase, Inhibition |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| AOP:209 | Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP | Gastrointestinal system disease | - | 0.12 | KE:1286 | Down Regulation, GSS and GSTs gene | |
| AOP:263 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Mouse, Rat, Lemna minor, Human, Caenorhabditis elegans | 0.75 | KE:1771 | Decrease, Adenosine triphosphate pool |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| KE:1821 | Decrease, Cell proliferation | ||||||
| AOP:264 | Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death | Unclassified | Under Development | 0.75 | KE:1771 | Decrease, Adenosine triphosphate pool | |
| KE:55 | Increase, Cell injury/death | ||||||
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:265 | Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium | Unclassified | Under Development | 0.5 | KE:55 | Increase, Cell injury/death | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:266 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity | Unclassified | Under Development | 0.5 | KE:1771 | Decrease, Adenosine triphosphate pool | |
| KE:55 | Increase, Cell injury/death | ||||||
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:267 | Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion | Unclassified | Under Development | 0.4 | KE:1821 | Decrease, Cell proliferation | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:268 | Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling | Unclassified | Under Development | 0.5 | KE:55 | Increase, Cell injury/death | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:271 | Inhibition of thyroid peroxidase leading to impaired fertility in fish | Unclassified | Under Development | Fish | 0.4 | KE:279 | Thyroperoxidase, Inhibition |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| AOP:281 | Acetylcholinesterase Inhibition Leading to Neurodegeneration | Nervous system disease | - | 0.3 | KE:12 | Acetylcholinesterase (AchE) Inhibition | |
| KE:55 | Increase, Cell injury/death | ||||||
| KE:389 | Increased, Intracellular Calcium overload | ||||||
| AOP:282 | Adverse outcome pathway on photochemical toxicity initiated by light exposure | Unclassified | Under Review | Human | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:298 | Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer via chronic ROS | Cancer; Gastrointestinal system disease | Under Review | Homo sapiens | 0.33 | KE:1753 | Chronic reactive oxygen species |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:310 | Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR | Unclassified | - | Zebrafish | 0.17 | KE:18 | Activation, AhR |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:312 | Acetylcholinesterase Inhibition leading to Acute Mortality via Impaired Coordination & Movement | Unclassified | - | 0.17 | KE:12 | Acetylcholinesterase (AchE) Inhibition | |
| AOP:324 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death | Unclassified | - | Fish | 0.5 | KE:55 | Increase, Cell injury/death |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:325 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death | Unclassified | - | Fish | 0.5 | KE:55 | Increase, Cell injury/death |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:326 | Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell death | Unclassified | - | Fish | 0.5 | KE:55 | Increase, Cell injury/death |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:327 | Excessive reactive oxygen species production leading to mortality (1) | Unclassified | - | Daphnia magna | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:328 | Excessive reactive oxygen species production leading to mortality (2) | Unclassified | - | Daphnia magna | 0.4 | KE:1771 | Decrease, Adenosine triphosphate pool |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:329 | Excessive reactive oxygen species production leading to mortality (3) | Unclassified | - | Daphnia magna, Paracyclopina nana | 0.4 | KE:1771 | Decrease, Adenosine triphosphate pool |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:330 | Excessive reactive oxygen species production leading to mortality (4) | Unclassified | - | Daphnia magna | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:331 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and reduced cell proliferation | Unclassified | - | Daphnia magna, Daphnia middendorffiana, Daphnia pulex, Daphnia pulicaria, Daphnia parvula | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:1505 | Cell cycle, disrupted | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:332 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation | Unclassified | - | 0.6 | KE:1821 | Decrease, Cell proliferation | |
| KE:1505 | Cell cycle, disrupted | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:333 | Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation | Unclassified | - | 0.8 | KE:1821 | Decrease, Cell proliferation | |
| KE:1771 | Decrease, Adenosine triphosphate pool | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:363 | Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure | Unclassified | Under Review | Zebrafish | 0.25 | KE:279 | Thyroperoxidase, Inhibition |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| AOP:364 | Thyroperoxidase inhibition leading to altered visual function via decreased eye size | Unclassified | Under Development | 0.25 | KE:279 | Thyroperoxidase, Inhibition | |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| AOP:365 | Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning | Unclassified | Under Development | 0.25 | KE:279 | Thyroperoxidase, Inhibition | |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| AOP:399 | Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) | Unclassified | - | Zebrafish | 0.25 | KE:1821 | Decrease, Cell proliferation |
| KE:1884 | Inhibition of Fyna | ||||||
| AOP:413 | Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure | Unclassified | - | Fish, Mice | 0.5 | KE:1607 | Increase, Necrosis |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:926 | Oxidation, Glutathione (To be considered with MIE) | ||||||
| AOP:414 | Aryl hydrocarbon receptor activation leading to lung fibrosis through TGF-β dependent fibrosis toxicity pathway | Musculoskeletal system disease; Respiratory system disease | - | 0.2 | KE:18 | Activation, AhR | |
| AOP:415 | Aryl hydrocarbon receptor activation leading to lung fibrosis through IL-6 toxicity pathway | Musculoskeletal system disease; Respiratory system disease | - | 0.2 | KE:18 | Activation, AhR | |
| AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.5 | KE:18 | Activation, AhR | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1669 | Increased, DNA damage and mutation | ||||||
| AOP:417 | Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway | Cancer | - | 0.4 | KE:18 | Activation, AhR | |
| KE:1669 | Increased, DNA damage and mutation | ||||||
| AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory system disease | - | 0.6 | KE:18 | Activation, AhR | |
| KE:1825 | Increase, Cell death | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory system disease | - | 0.5 | KE:18 | Activation, AhR | |
| KE:1262 | Apoptosis | ||||||
| AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.5 | KE:18 | Activation, AhR | |
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:423 | Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway | Unclassified | - | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular system disease | - | 0.08 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic disease; Cancer | Under Development | Humans, Mice | 0.56 | KE:18 | Activation, AhR |
| KE:1971 | Increased, tumor growth | ||||||
| KE:149 | Increase, Inflammation | ||||||
| KE:1241 | Increased, Motility | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic disease; Cancer | Under Development | Human and other cells in culture, Human, Mice, Rat, Canine heartworm nematode, Yeast | 0.4 | KE:1554 | Increase Chromosomal Aberrations |
| KE:155 | Inadequate DNA repair | ||||||
| KE:1669 | Increased, DNA damage and mutation | ||||||
| KE:1172 | Increased activation, Nuclear factor kappa B (NF-kB) | ||||||
| AOP:445 | Estrogen Receptor Alpha Agonism leads to Impaired Reproduction | Reproductive system disease | - | 0.12 | KE:1065 | Activation, estrogen receptor alpha | |
| AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory system disease | - | 0.35 | KE:1115 | Increase, Reactive oxygen species | |
| KE:165 | Activation, Long term AHR receptor driven direct and indirect gene expression changes | ||||||
| KE:18 | Activation, AhR | ||||||
| KE:1198 | Activation, Macrophages | ||||||
| KE:149 | Increase, Inflammation | ||||||
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:447 | Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways | Urinary system disease | - | 0.17 | KE:1097 | Occurrence, renal proximal tubular necrosis | |
| KE:202 | Inhibition, Nuclear factor kappa B (NF-kB) | ||||||
| AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular system disease | - | 0.12 | KE:1198 | Activation, Macrophages | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous system disease | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.14 | KE:12 | Acetylcholinesterase (AchE) Inhibition |
| AOP:453 | Reactive oxygen species and subsequent oxidative stress lead to increased incidence of digestive morbidity and mortality in the general population | Gastrointestinal system disease | - | 0.15 | KE:1198 | Activation, Macrophages | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:455 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development | Musculoskeletal system disease | Under Review | Zebrafish, Mouse, Human, Sebastiscus marmoratus, Salmo salar, Chicken | 0.17 | KE:18 | Activation, AhR |
| AOP:456 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity | Unclassified | Under Review | Zebrafish, Mouse, Human, Chicken | 0.17 | KE:18 | Activation, AhR |
| AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal system disease | - | 0.27 | KE:149 | Increase, Inflammation | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:469 | Reactive oxygen speicies overproduction leading to increased digestive morbidity and mortality in generation population | Gastrointestinal system disease | - | 0.15 | KE:1198 | Activation, Macrophages | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:472 | DNA adduct formation leading to kidney failure | Urinary system disease | - | 0.44 | KE:1097 | Occurrence, renal proximal tubular necrosis | |
| KE:1825 | Increase, Cell death | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:149 | Increase, Inflammation | ||||||
| AOP:494 | AhR activation leading to liver fibrosis | Gastrointestinal system disease | - | Mus musculus, Homo sapiens | 0.33 | KE:18 | Activation, AhR |
| KE:55 | Increase, Cell injury/death | ||||||
| AOP:503 | Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation | Reproductive system disease; Cancer | Under Review | Human, Mouse | 0.17 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular system disease | - | Human, Mouse, Zebrafish | 0.06 | KE:1115 | Increase, Reactive oxygen species |
| AOP:536 | Estrogen receptor agonism leading to reduced survival and population growth due to renal failure | Unclassified | - | 0.17 | KE:111 | Agonism, Estrogen receptor | |
| AOP:537 | Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver | Unclassified | - | 0.2 | KE:111 | Agonism, Estrogen receptor | |
| AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.33 | KE:1115 | Increase, Reactive oxygen species | |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:541 | Excessive ROS generation leading to increased incidence of vascular calcification by VSMC phenotype switching | Cardiovascular system disease | - | 0.23 | KE:1493 | Increased Pro-inflammatory mediators | |
| KE:1198 | Activation, Macrophages | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:559 | Inhibition of acetylcholinesterase (AChE) leading to arrhythmias | Symptom | - | Human and other cells in culture, Rattus norvegicus, Dogs, Sus scrofa, Zebrafish, Insecta sp. BOLD:AAN5199 | 0.2 | KE:12 | Acetylcholinesterase (AchE) Inhibition |
| AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive system disease; Endocrine system disease | - | Rat, Mouse, Zebra fish, Human | 0.33 | KE:18 | Activation, AhR |
| KE:1262 | Apoptosis |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.5 | KE:279 | Thyroperoxidase, Inhibition |
| KE:757 | Hippocampal anatomy, Altered | ||||||
| KE:402 | Cognitive function, decreased | ||||||
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| AOP:392 | Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation | Unclassified | Under Development | Humans | 0.6 | KE:1497 | Increased, recruitment of inflammatory cells |
| KE:1868 | Hyperinflammation | ||||||
| KE:1867 | Bradykinin system, hyperactivated | ||||||
| AOP:405 | Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function | Cognitive disorder | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.4 | KE:12 | Acetylcholinesterase (AchE) Inhibition |
| KE:402 | Cognitive function, decreased | ||||||
| AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Mouse, Monkey, Human | 0.38 | KE:18 | Activation, AhR |
| KE:295 | Induction, Upregulation of glucuronyltransferase activity | ||||||
| KE:402 | Cognitive function, decreased | ||||||
| AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Human, Mouse, Rat | 0.44 | KE:18 | Activation, AhR |
| KE:850 | Induction, CYP1A2/CYP1A5 | ||||||
| KE:402 | Cognitive function, decreased | ||||||
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive disorder | - | Human | 0.43 | KE:1869 | Diminished protective oxidative stress response |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:402 | Cognitive function, decreased | ||||||
| AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | Human, Mouse, Rat | 0.6 | KE:885 | Increase, Cancer |
| KE:149 | Increase, Inflammation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | Human, Mouse, Rat | 0.6 | KE:885 | Increase, Cancer |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1060 | Alteration, lipid metabolism |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.